Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
IMMX 
Immix Biopharma Inc (IMMX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: IMMX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8
1 Year Target Price $8
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -21.19% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 65.33M USD | Price to earnings Ratio - | 1Y Target Price 8 |
Price to earnings Ratio - | 1Y Target Price 8 | ||
Volume (30-day avg) 1 | Beta 0.25 | 52 Weeks Range 1.26 - 3.20 | Updated Date 09/17/2025 |
52 Weeks Range 1.26 - 3.20 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.77 |
Earnings Date
Report Date 2025-09-03 | When - | Estimate -0.21 | Actual -0.22 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -66.85% | Return on Equity (TTM) -162.04% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 54735511 | Price to Sales(TTM) - |
Enterprise Value 54735511 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.37 | Shares Outstanding 32665300 | Shares Floating 20192528 |
Shares Outstanding 32665300 | Shares Floating 20192528 | ||
Percent Insiders 34.4 | Percent Institutions 8.46 |
Upturn AI SWOT
Immix Biopharma Inc
Company Overview
History and Background
Immix Biopharma Inc. is a biopharmaceutical company focused on developing therapies for cancer and other life-threatening diseases. Founded in 2012, Immix Biopharma leverages its proprietary SMARxT platform to design and develop Targeted Therapeutics, including cancer therapeutics.
Core Business Areas
- Drug Development: Focuses on developing novel therapeutic candidates using the SMARxT platform, primarily in oncology.
Leadership and Structure
The leadership team includes key executives in research and development, clinical operations, and business development. The organizational structure is typical of a biotechnology company, with departments focused on research, preclinical studies, clinical trials, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Description of Product 1, include any market share data or number of users or revenue from this product. Who are the competitors for this product: IMX-110 is the lead drug candidate, an intravenously delivered product being developed for multiple cancers. Currently in clinical trials. Competitors include companies developing similar targeted therapies and standard chemotherapy treatments.
- Description of Product 2, include any market share data or number of users or revenue from this product. Who are the competitors for this product: Proprietary drug delivery platform. Revenue is derived through potential licensing or partnered drug development programs. No direct competitors to this platform, the competition comes from alternative drug delivery platforms for targeted therapies
- Product Name 1: IMX-110 (clinical stage)
- Product Name 2: SMARxT Platform
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense competition, high R&D costs, and a complex regulatory environment. The oncology market is particularly large and growing, driven by an aging population and advancements in cancer diagnostics and treatments.
Positioning
Immix Biopharma Inc. is positioned as a drug developer leveraging its SMARxT platform to create targeted therapeutics in oncology.
Total Addressable Market (TAM)
The global oncology market is estimated to be in the hundreds of billions of dollars. Immix Biopharma Inc. targets specific cancer subtypes within this large market.
Upturn SWOT Analysis
Strengths
- Proprietary SMARxT platform
- Targeted therapy approach
- Potential for high value drug candidates
- Experienced management team
Weaknesses
- Limited financial resources
- High R&D risk
- Reliance on clinical trial success
- Small market capitalization
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new cancer indications
- Positive clinical trial data
- Regulatory approvals
Threats
- Clinical trial failures
- Competition from larger pharmaceutical companies
- Regulatory hurdles
- Patent expirations
Competitors and Market Share
Key Competitors
- MRTX
- ARRY
- NKTR
Competitive Landscape
Immix Biopharma Inc. faces competition from larger pharmaceutical companies with greater resources and established pipelines. Its competitive advantage lies in its SMARxT platform and targeted therapy approach.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the company's stage of development. Growth is expected to accelerate with clinical trial progress and potential regulatory approvals.
Future Projections: Future growth is highly dependent on the success of IMX-110 and other drug candidates. Analyst estimates vary widely based on clinical trial outcomes and market potential.
Recent Initiatives: Recent initiatives include ongoing clinical trials for IMX-110, expansion of the SMARxT platform, and exploration of potential partnerships.
Summary
Immix Biopharma is a high-risk, high-reward clinical-stage company. The company's SMARxT platform and targeted therapy approach represent strengths, but clinical trial successes and financial stability are key challenges. Growth hinges on positive data and regulatory approvals, and future partnerships are crucial for long-term viability. Its competitors have a greater market share and capital resources, placing IMMX in a weaker position against the other competitors. Investors should be prepared for high volatility.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Website
- Analyst Reports
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Investment decisions should be based on individual risk tolerance and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Immix Biopharma Inc
Exchange NASDAQ | Headquaters Los Angeles, CA, United States | ||
IPO Launch date 2021-12-16 | Co-Founder, CEO & Chairman Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 18 | Website https://www.immixbio.com |
Full time employees 18 | Website https://www.immixbio.com | ||
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.